NCT04451928 is a clinical trial of Serum sample analysis in Preterm Birth, sponsored by Ismail Biyik.

Who is sponsoring NCT04451928?

NCT04451928 is sponsored by Ismail Biyik.

What drugs are being tested in NCT04451928?

Interventions in NCT04451928: Serum sample analysis.

What condition does NCT04451928 study?

NCT04451928 studies Preterm Birth.

Is NCT04451928 still recruiting?

NCT04451928 is currently completed. Last updated 3 March 2021.

Last reviewed 2021-03-03 · How we verify

NCT04451928

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prediction of Preterm Delivery by Serum Ischemia Modified Albumin, Biglycan and Decorin Levels in Women With Threatened Preterm Labour

Completed Last updated 3 March 2021

What this trial tests

trial testing Serum sample analysis in Preterm Birth in 51 participants. Completed in 5 February 2021.

Timeline

1 December 2019

Primary endpoint
5 February 2021

5 February 2021

Quick facts

Lead sponsor	Ismail Biyik
Status	Completed
Study type	OBSERVATIONAL
Enrollment	51
Start date	1 December 2019
Primary completion	5 February 2021
Estimated completion	5 February 2021
Sites	1 location across Turkey (Türkiye)

Drugs / interventions tested

Serum sample analysis

Conditions studied

Preterm Birth — all drugs for Preterm Birth →

Sponsor

Ismail Biyik

Who can join

Adults 18 to 42, female only, with Preterm Birth. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study, the levels of ischemia modified albumin, biglycan and decorin in the serums of pregnant women hospitalized for preterm labor will be examined. Their serum levels will be compared between women having preterm and term delivery. Their accuracy will be asessed in predicting preterm birth.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Prediction of Preterm Delivery Using Serum Ischemia Modified Albumin, Biglycan, and Decorin Levels in Women with Threatened Preterm Labor.
Biyik I, Soysal C, Ince OUO, Durmus S, et al · · 2023 · PMID 38141595 · DOI 10.1055/s-0043-1772593

Verify or expand the search:

Other recruiting trials for Preterm Birth

Currently open trials in the same condition.

NCT07265583 — Early Prediction of Lung Injury in Preterm Infants Score · recruiting
NCT07305935 — Comparison of Early Caffeine Administration Vs Supportive Therapy in Preventing Acute Kidney Injury · NA · recruiting
NCT07192393 — Health-Related Quality-of-Life and Household Financial and Wellbeing Impacts of Prematurity and Necrotising Enterocoliti · recruiting
NCT06826859 — Daily Aspirin vs Split Dosing in High-risk Pregnancies (DASH) · Phase 1, PHASE2 · recruiting
NCT07231432 — Promoting Kangaroo Care for Preterm or Low Birthweight Infants in Rural India · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04451928 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ismail Biyik
Last refreshed: 3 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04451928.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing